Study guide

Section 4.8: Clinical Pharmacology: Respiratory & Pulmonary Disorders

Saudi Pharmacist Licensure Examination SPLE - Pharmacist

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

Section 0.1: About the Saudi Pharmacist Licensure Examination (SPLE) Section 0.2: How to Study and Prep for the SPLE

2 Chapter 1: Basic Biomedical Sciences

Section 1.1: Human Physiology & Pathophysiology Foundations Section 1.2: Medical Biochemistry & Enzymology Section 1.3: Medical Microbiology & Immunology Section 1.4: Molecular Genetics & Pharmacogenomics Foundations

3 Chapter 2: Pharmaceutical Sciences

Section 2.1: Medicinal Chemistry & Structure-Activity Relationships (SAR) Section 2.2: Drug ADME (Absorption, Distribution, Metabolism, Excretion) Section 2.3: General Pharmacology: Mechanisms of Drug Action Section 2.4: General Toxicology: Overdose, Antidotes & Adverse Drug Reactions (ADRs) Section 2.5: Pharmacognosy: Natural Products & Dietary Supplements Section 2.6: Basic Pharmaceutics & Dosage Form Design Section 2.7: Biopharmaceutics & Drug Delivery Systems Section 2.8: Applied Pharmacokinetics (PK): One-Compartment Models Section 2.9: Non-linear and Multi-compartment Pharmacokinetics Section 2.10: Sterile Compounding: Techniques & Quality Standards Section 2.11: Non-sterile Compounding & Product Formulation Section 2.12: Pharmaceutical Calculations: Dosing and Strengths Section 2.13: Pharmaceutical Calculations: Dilutions and Reconstitution Section 2.14: Pharmaceutical Calculations: Osmolarity, Milliequivalents, and Alligations

4 Chapter 3: Social, Behavioral, and Administrative Sciences

Section 3.1: Saudi Arabian Healthcare System & Public Health Policies Section 3.2: Pharmacoepidemiology & Post-Marketing Drug Surveillance Section 3.3: Pharmacovigilance & Drug Safety Monitoring in Saudi Arabia Section 3.4: Pharmacoeconomic Principles & Cost-Benefit Analysis Section 3.5: Pharmacy Management, Inventory, and Operations Section 3.6: Saudi Pharmacy Law & SFDA Regulations Section 3.7: Biostatistics, Clinical Trial Design & Literature Evaluation Section 3.8: Professional Ethics, Communication, and Dispensing Systems

5 Chapter 4: Clinical Sciences

Section 4.1: Drug Information Services & Evidence-Based Medicine Section 4.2: Clinical Pharmacokinetics & Therapeutic Drug Monitoring (TDM) Section 4.3: Clinical Pharmacogenomics & Personalized Therapeutics Section 4.4: Disease Prevention, Wellness, and Immunization Schedules Section 4.5: Patient Assessment & Physical Examination Interpretation Section 4.6: Clinical Pharmacology: Cardiovascular Disorders Section 4.7: Clinical Pharmacology: Renal & Urological Disorders Section 4.8: Clinical Pharmacology: Respiratory & Pulmonary Disorders Section 4.9: Clinical Pharmacology: Endocrine & Metabolic Disorders Section 4.10: Clinical Pharmacology: Infectious Diseases & Antimicrobial Stewardship Section 4.11: Clinical Pharmacology: Neurological & Psychiatric Disorders Section 4.12: Clinical Pharmacology: Oncology, Immunology, and Hematology Section 4.13: Clinical Pharmacology: Gastrointestinal & Hepatic Disorders Section 4.14: Therapeutic Decision-Making in Special Populations (Geriatrics, Pediatrics, Pregnancy, Lactation)

Section 4.8: Clinical Pharmacology: Respiratory & Pulmonary Disorders

Key Takeaways Explain This Topic AI

Inhaled corticosteroids (ICS) combined with formoterol is now the preferred reliever in asthma across all steps under GINA guidelines, replacing SABA-only therapy.

COPD pharmacological therapy is guided by the GOLD ABE assessment tool, where dual bronchodilation (LAMA + LABA) is preferred for symptomatic or exacerbation-prone patients (Group B and E).

Intranasal corticosteroids represent the first-line and most effective treatment class for moderate-to-severe allergic rhinitis.

Pulmonary arterial hypertension (PAH) treatment starts with vasoreactivity testing; responders receive high-dose CCBs, while non-responders require target-specific therapies like prostacyclins, endothelin receptor antagonists (ERAs), or PDE-5 inhibitors.

Last updated: July 2026

Clinical Pharmacology: Respiratory & Pulmonary Disorders

Respiratory and pulmonary disorders represent a significant portion of the Saudi Pharmacist Licensure Examination (SPLE) clinical sciences blueprint. Pharmacists must understand the pathophysiology, therapeutic guidelines, drug mechanisms of action, adverse effect profiles, and safety monitoring requirements for asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and pulmonary arterial hypertension (PAH).

1. Asthma Management (GINA 2024 / Saudi Guidelines)

Asthma is a heterogeneous chronic inflammatory disease of the airways characterized by bronchial hyperresponsiveness and variable airflow obstruction. The Global Initiative for Asthma (GINA) guidelines specify two tracks for treatment, with Track 1 being the preferred approach for adult and adolescent patients.

GINA Tracks Overview

Track 1 (Preferred): Uses low-dose inhaled corticosteroid (ICS) + formoterol as the reliever across all steps. This approach ensures that the patient receives anti-inflammatory therapy whenever reliever therapy is needed, mitigating the risk of severe exacerbations. SABA-only treatment is no longer recommended due to the risk of rebound hyperresponsiveness and increased mortality.

Track 2 (Alternative): Uses a short-acting beta-2 agonist (SABA) as the reliever. This track requires strict adherence to daily maintenance ICS to prevent exacerbations. If a patient is poorly adherent to their maintenance inhaler, they are at high risk of severe asthma attacks.

Stepwise Management (Ages 12+)

  • Step Track 1 (Preferred - Reliever: Low-dose ICS-formoterol PRN) Track 2 (Alternative - Reliever: SABA PRN)
  • Step 1 & 2 As-needed (PRN) low-dose ICS-formoterol Low-dose maintenance ICS + PRN SABA
  • Step 3 Maintenance low-dose ICS-formoterol + PRN reliever Maintenance low-dose ICS-LABA + PRN SABA
  • Step 4 Maintenance medium-dose ICS-formoterol + PRN reliever Maintenance medium/high-dose ICS-LABA + PRN SABA

Step 5 Add LAMA (e.g., tiotropium), refer for phenotypic assessment (biologics) Add LAMA, refer for phenotypic assessment (biologics)

Severe Asthma & Biologics

For patients on Step 5 therapy, phenotypic assessment guides the selection of monoclonal antibodies:

Omalizumab: Anti-IgE recombinant antibody. Indicated for severe allergic asthma with elevated serum IgE levels.

Mepolizumab & Benralizumab: Anti-interleukin-5 (IL-5) antibodies (Mepolizumab targets IL-5 ligand, Benralizumab targets IL-5 receptor alpha). Indicated for severe eosinophilic asthma.

Dupilumab: Anti-IL-4 receptor alpha antibody (blocks IL-4 and IL-13 signaling). Indicated for severe eosinophilic asthma or patients dependent on oral corticosteroids.

2. COPD Management (GOLD 2024 / Saudi Guidelines)

Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent, progressive respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities (typically caused by tobacco smoke or biomass exposure). Unlike asthma, COPD is generally progressive and not fully reversible.

GOLD ABE Assessment Tool

COPD pharmacotherapy is guided by the patient's exacerbation history and symptom burden, measured by the modified Medical Research Council (mMRC) dyspnea scale or the COPD Assessment Test (CAT). Exacerbation History:

>= 2 moderate exacerbations OR

>= 1 leading to hospitalization -----> Group E (LAMA + LABA; consider adding ICS if blood eosinophils >= 300 cells/mcL)

0-1 moderate exacerbations (none leading to hospitalization):

  • mMRC 0-1, CAT < 10 -----> Group A (Single bronchodilator: LAMA or LABA)
  • mMRC >= 2, CAT >= 10 -----> Group B (LAMA + LABA)
  • Pharmacotherapy Classes and Roles

Long-Acting Muscarinic Antagonists (LAMA): e.g., Tiotropium, Umeclidinium, Glycopyrrolate. Block M3 receptors on airway smooth muscle, causing bronchodilation. They are highly effective at reducing exacerbation frequency.

Long-Acting Beta-2 Agonists (LABA): e.g., Salmeterol, Formoterol, Vilanterol. Stimulate beta-2 adrenergic receptors, leading to bronchodilation.

Inhaled Corticosteroids (ICS): e.g., Fluticasone, Budesonide. Never used as monotherapy in COPD due to lack of efficacy and an increased risk of pneumonia. ICS should be added to LAMA+LABA dual therapy (triple therapy) only if the patient has a history of frequent exacerbations and a blood eosinophil count of >= 300 cells/mcL (or >= 100 cells/mcL with >= 2 moderate exacerbations or 1 hospitalization).

3. Allergic Rhinitis

Allergic rhinitis is an immunoglobulin E (IgE)-mediated inflammatory response of the nasal mucosa to airborne allergens. Pharmacists must distinguish between the efficacy and safety profiles of available treatments:

Intranasal Corticosteroids (e.g., Fluticasone, Mometasone): The most effective treatment class for moderate-to-severe symptoms. They downregulate local inflammatory cytokines. Side effects include nasal dryness, burning, and epistaxis.

Antihistamines (H1-receptor antagonists):

First-Generation (e.g., Diphenhydramine, Chlorpheniramine, Hydroxyzine): Highly lipophilic and cross the blood-brain barrier. They cause marked sedation, cognitive impairment, and anticholinergic effects (dry mouth, urinary retention, blurred vision). They are avoided in elderly patients.

Second-Generation (e.g., Loratadine, Cetirizine, Fexofenadine): Highly hydrophilic and do not readily cross the blood-brain barrier. Fexofenadine and Loratadine are non-sedating, while Cetirizine can cause mild sedation in sensitive individuals.

Intranasal (e.g., Azelastine, Olopatadine): Provide rapid symptom relief with a bitter taste as a common side effect.

Leukotriene Receptor Antagonists (e.g., Montelukast): Indicated for patients with concomitant asthma. However, pharmacists must counsel on the FDA Black Box Warning for serious neuropsychiatric events, including agitation, depression, and suicidal ideation.

4. Pulmonary Arterial Hypertension (PAH)

PAH (WHO Group 1) is a rare, progressive disease characterized by elevated pulmonary vascular resistance leading to right ventricular failure. It is diagnosed by right heart catheterization showing a mean pulmonary artery pressure (mPAP) > 20 mmHg with normal pulmonary capillary wedge pressure (PCWP <= 15 mmHg).

Vasoreactivity Testing & Treatment Algorithm

All patients must undergo acute vasoreactivity testing during right heart catheterization, usually using inhaled nitric oxide:

Responders (Positive Response): Defined as a decrease in mPAP by >= 10 mmHg to an absolute value <= 40 mmHg with a stable or increased cardiac output. These patients are treated with high-dose oral Calcium Channel Blockers (CCBs) : Amlodipine, Nifedipine ER, or Diltiazem. Verapamil is avoided due to negative inotropic effects.

Non-responders (Negative Response): Require specialized PAH-targeted drug classes:

Drug Class Examples Mechanism of Action Clinical Considerations & Monitoring

Prostacyclin Analogs & Receptor Agonists Epoprostenol (IV), Treprostinil (IV/SC/inhaled/oral), Iloprost (inhaled), Selexipag (oral) Direct vasodilation of pulmonary vascular beds; inhibits platelet aggregation Epoprostenol has a short half-life (~6 mins); abrupt interruption can cause fatal rebound pulmonary hypertension. SC treprostinil causes severe infusion site pain.

Endothelin Receptor Antagonists (ERAs) Bosentan, Ambrisentan, Macitentan Block endothelin receptors (ET-A and/or ET-B), preventing vasoconstriction Bosentan has a black box warning for hepatotoxicity (requires monthly LFT monitoring). All ERAs are highly teratogenic and require monthly pregnancy tests (REMS program).

PDE-5 Inhibitors Sildenafil, Tadalafil Inhibit PDE-5, preventing degradation of cGMP, causing nitric oxide-mediated vasodilation Contraindicated with organic nitrates (e.g., nitroglycerin) and soluble guanylate cyclase stimulators due to severe hypotension.

Soluble Guanylate Cyclase (sGC) Stimulators Riociguat Directly stimulates sGC and sensitizes it to endogenous nitric oxide, increasing cGMP Contraindicated with nitrates and PDE-5 inhibitors. Highly teratogenic (REMS program).